Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib extension study in advanced solid tumors
NCT02171650Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoint: Incidence and severity of Adverse Events up to 18 months. Started Dec 2004; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02171650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171650.